#VisualAbstract: Ruxolitinib improved glucocorticoid-refractory chronic graft-versus-host disease
1. Ruxolitinib was shown to significantly improve failure-free survival for glucocorticoid-refractory chronic graft-versus-host disease (GVHD) compared to control therapy. 2. ...